- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03421483
Assessing Colonic Folate Absorption & Metabolism
October 25, 2022 updated by: Deborah O'Connor, The Hospital for Sick Children
Factors Affecting Colonic Folate Absorption and Metabolism in Humans
Folate, a B-vitamin, is necessary in metabolic processes such as amino acid and nucleotide synthesis.
Since folate cannot be synthesized by mammals, it must be consumed as foods and dietary supplements or generated by bacteria present in the colon.
There are many known adverse health outcomes associated with folate deficiency in humans such as neural tube defects in newborns and colorectal cancer in adults.
It has also been proposed that supra-physiological folate status can also be detrimental since it can lead to changes in immune function and the masking of vitamin B12 deficiency.
It is generally believed that dietary sources of folate are primarily absorbed in the small intestine, however recent evidence suggests the colon may play a more significant role in the absorption of folate than previously understood.
The aim of this study is to assess how folic acid supplementation influences colonic folate absorption and metabolism in humans.
This will be accomplished by assessing the expression of two major folate transporters responsible for folate absorption in the colon.
Participants will be randomized to receive multivitamins with either 0 or 400 µg folic acid during a 16-week randomized clinical trial in which blood and colonic tissue biopsies will be collected and analyzed.
The total folate concentrations and expression of folate transporters in colonocytes will be measured to confirm levels and evaluate the impact of supplemental folic acid.
The expression of two folate hydrolases responsible for converting naturally occurring folate to its bioavailable form will also be evaluated.
This work will lead to a deeper understanding of colonic folate absorption and metabolism, resulting in more appropriate dietary and supplemental folate recommendations.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The vitamin folate is necessary for one-carbon metabolism in processes such as amino acid and nucleotide synthesis.
As folate cannot be synthesized by mammals, it must be sourced from the diet and dietary supplements or generated by bacterial species present in the colon.
There are a number of well-established adverse health outcomes associated with folate deficiency in humans, including congenital neural tube defects in newborns and colorectal cancer in adults.
It has been proposed supra-physiological folate status can also be detrimental since it can lead to changes in immune function and the masking of vitamin B12 deficiency.
It is generally believed that dietary sources of folate are primarily absorbed in the small intestine, however recent evidence from our team and others suggests that the colon may play a greater role in absorption of folate than previously understood.
Specifically the amount of folate in the colon, much of it generated by the microbiome, can exceed dietary intakes of folate from natural sources.
There are a number of gaps in knowledge regarding colonic folate absorption in humans.
It is not known to what degree folate specific transporters such as proton coupled folate transporter (PCFT) and reduced folate carrier (RFC) are present in the colon of healthy humans.
To date, the majority of studies conducted identifying the presence of RFC and PCFT in colonocytes have been performed using cell lines or tissue harvested from organ donors.
To our knowledge, no study has investigated the mRNA and protein concentrations of both RFC and PCFT present in human colonic tissue retrieved as biopsies.
It also remains to be determined if folate status influences RFC and PCFT expression at the level of the colon.
Secondly, it remains unclear to what degree the two intestinal folate hydrolases, glutamate carboxypeptidase II (GCPII) and γ-glutamyl hydrolase (GGH) are present in colonic mucosa.
To gain a more thorough understanding of the fundamental processes involved in folate absorption in the colon of humans, the following three objectives are proposed.
The primary objective is to evaluate the impact of 0 and 400 µg supplemental folic acid on total folate concentrations within the colonic mucosa by measuring folate levels.
The secondary objectives include evaluating the impact of 0 and 400 µg supplemental folic acid on the regulation of PCFT and RFC in the ileum and colon by assessing the expression of mRNA transcripts and proteins, and determining the degree to which GCPII and GGH are present in the lumen of the ileum and colon by quantifying enzyme activity and expression of mRNA transcripts and proteins.
To accomplish this, a 16-week longitudinal open-labelled randomized clinical trial will be conducted.
Recruitment and screening will require three separate steps comprised of an initial invitation to participate, followed by a telephone screening session to determine eligibility and finally a baseline in-person study visit prior to enrollment into the intervention phase of the study.
Once enrolled, participants will be asked to follow a diet low in synthetic folic acid for the duration of the study.
At enrollment, subjects will be randomized to receive a multivitamin supplement and either 0 or 400 µg folic acid.
Follow-up study visits will take place at week 8 and week 16 where anthropometric measurements, blood and colonic tissue biopsies (Week 16 only) from the terminal ileum, cecum, ascending colon, and descending colon will be collected for analysis.
24-hour dietary recalls will be collected throughout the study to observe folate and caloric intake.
Plasma, RBC folate levels, and colonic mucosa folate content will be determined via microbial assay.
GCPII and GGH enzyme activity will be determined according to the Krumdieck and Baugh method with modification.
PCFT and RFC expression will be determined via semi-quantitative real-time PCR and protein samples will be extracted in a Western Blot Analysis using RIPA lysis and extraction buffer.
The proposed study will further our understanding of the fundamental processes of folate metabolism and absorption in the colon.
Results from this study may help to establish the optimal intakes of dietary folate, meeting the requirements of humans, without the potential health risks related to over-exposure to folate.
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males >18 years old and <75 years old;
- Females who are pre-menopausal that have had a hysterectomy or tubal ligation, post-menopausal (at least 1 year) and <75 years old;
- Describe themselves as generally healthy.
- Recommended to have a colonoscopy examination by their Doctor
Exclusion Criteria:
- They have a history of gastrointestinal disease (such as Crohn's disease, ulcerative colitis, celiac disease) and/ or gastrointestinal cancers;
- They have had a previous colon resection;
- They are regularly using medications that may affect gastrointestinal pH or folate metabolism (e.g. proton pump inhibitors, phenytoin, phenobarbital, primidone, or have used oral antibiotics within the last 2 weeks);
- On a regular basis they consume >2 alcoholic drinks/day for women or >3/day for men;
- They are currently smokers;
- They are folic acid supplement users or have used folic acid supplements or multivitamins containing folic acid in the last 4 months;
- They have a bleeding disorder (such as hemophilia)
- They are unlikely able to discontinue anti-coagulant therapy prior to colonoscopy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Folic Acid supplementation
Participants receive an adult multivitamin supplement along with a folic acid supplement
|
Participants receive a 400 microgram Folic Acid supplement
Participants will receive an adult multivitamin supplement
|
Placebo Comparator: No supplementation
Participants only receive an adult multivitamin supplement
|
Participants will receive an adult multivitamin supplement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Colonic folate levels
Time Frame: 4 months
|
Evaluate the impact of 0 and 400 µg supplemental folic acid on total folate concentrations within the colonic mucosa by measuring folate levels
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PCFT
Time Frame: 4 months
|
Evaluate the impact of 0 and 400 µg supplemental folic acid on the regulation of PCFT in the ileum and colon by assessing the expression of mRNA transcripts and proteins
|
4 months
|
RFC
Time Frame: 4 months
|
Evaluate the impact of 0 and 400 µg supplemental folic acid on the regulation of RFC in the ileum and colon by assessing the expression of mRNA transcripts and proteins
|
4 months
|
GCPII
Time Frame: 4 months
|
Determine the degree to which GCPII is present in the lumen of the ileum and colon by quantifying enzyme activity and expression of mRNA transcripts and proteins
|
4 months
|
GGH
Time Frame: 4 months
|
Determine the degree to which GGH is present in the lumen of the ileum and colon by quantifying enzyme activity and expression of mRNA transcripts and proteins
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US); 1998. Available from http://www.ncbi.nlm.nih.gov/books/NBK114310/
- Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochem J. 2011 Aug 1;437(3):357-72. doi: 10.1042/BJ20110326.
- Mason JB, Tang SY. Folate status and colorectal cancer risk: A 2016 update. Mol Aspects Med. 2017 Feb;53:73-79. doi: 10.1016/j.mam.2016.11.010. Epub 2016 Nov 24.
- De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, Fernandez B, Lee NS, Niyonsenga T. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med. 2007 Jul 12;357(2):135-42. doi: 10.1056/NEJMoa067103.
- Lakoff A, Fazili Z, Aufreiter S, Pfeiffer CM, Connolly B, Gregory JF 3rd, Pencharz PB, O'Connor DL. Folate is absorbed across the human colon: evidence by using enteric-coated caplets containing 13C-labeled [6S]-5-formyltetrahydrofolate. Am J Clin Nutr. 2014 Nov;100(5):1278-86. doi: 10.3945/ajcn.114.091785. Epub 2014 Sep 3.
- Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006 Dec 1;127(5):917-28. doi: 10.1016/j.cell.2006.09.041.
- Dudeja PK, Torania SA, Said HM. Evidence for the existence of a carrier-mediated folate uptake mechanism in human colonic luminal membranes. Am J Physiol. 1997 Jun;272(6 Pt 1):G1408-15. doi: 10.1152/ajpgi.1997.272.6.G1408.
- Kumar CK, Moyer MP, Dudeja PK, Said HM. A protein-tyrosine kinase-regulated, pH-dependent, carrier-mediated uptake system for folate in human normal colonic epithelial cell line NCM460. J Biol Chem. 1997 Mar 7;272(10):6226-31. doi: 10.1074/jbc.272.10.6226.
- Paniz C, Bertinato JF, Lucena MR, De Carli E, Amorim PMDS, Gomes GW, Palchetti CZ, Figueiredo MS, Pfeiffer CM, Fazili Z, Green R, Guerra-Shinohara EM. A Daily Dose of 5 mg Folic Acid for 90 Days Is Associated with Increased Serum Unmetabolized Folic Acid and Reduced Natural Killer Cell Cytotoxicity in Healthy Brazilian Adults. J Nutr. 2017 Sep;147(9):1677-1685. doi: 10.3945/jn.117.247445. Epub 2017 Jul 19.
- Chakraborty H, Nyarko KA, Goco N, Moore J, Moretti-Ferreira D, Murray JC, Wehby GL. Folic Acid Fortification and Women's Folate Levels in Selected Communities in Brazil - A First Look. Int J Vitam Nutr Res. 2014;84(5-6):286-94. doi: 10.1024/0300-9831/a000215.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 17, 2018
Primary Completion (Anticipated)
October 15, 2023
Study Completion (Anticipated)
October 15, 2023
Study Registration Dates
First Submitted
January 8, 2018
First Submitted That Met QC Criteria
January 29, 2018
First Posted (Actual)
February 5, 2018
Study Record Updates
Last Update Posted (Actual)
October 26, 2022
Last Update Submitted That Met QC Criteria
October 25, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000059584
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Folate
-
Wageningen Centre for Food SciencesWageningen UniversityCompletedHealthy | Folate BioavailabilityNetherlands
-
University of British ColumbiaCompleted
-
Universität des SaarlandesCompletedthe Effect of MTHFR C677T on Folate MetabolismGermany
-
Ludwig-Maximilians - University of MunichEuropean UnionCompletedPerinatal DHA and Folate Status | Neurological DevelopmentHungary, Germany, Spain
-
National Institute of Health and NutritionCompletedFolate Deficiency
-
Oklahoma State University Center for Health SciencesActive, not recruiting
-
University Medical Centre LjubljanaRecruitingBody Weight | IVF | Nutrient Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Folate Deficiency AnemiaSlovenia
-
University of California, DavisUniversity of California, San Francisco; Ethiopian Public Health Institute; Nutrition...Enrolling by invitationFolate Deficiency | Iodine Deficiency | Anemia, Macrocytic | Anemia Deficiency | Salt IntakeEthiopia
-
Affiliated Hospital of Nantong UniversityRecruitingCML | Treatment-free Remission | FolateChina
-
Cornell UniversityCenters for Disease Control and Prevention; St. John's Research Institute; Arogyavaram...Active, not recruiting
Clinical Trials on Folic Acid supplementation
-
University of Sao PauloNot yet recruitingObesity | Lupus ErythematosusBrazil
-
Wenzhou Medical UniversityUnknownArsenic Poisoning | Toxic Effect of Arsenic and Its Compounds
-
Wageningen UniversityZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedCognitive Decline | Cognitive SymptomsNetherlands
-
Poznan University of Life SciencesCompleted
-
University of TorontoIovate Health Sciences International IncCompletedExercise | Metabolism | Amino Acids, EssentialCanada
-
National Taiwan University HospitalUnknownAtrophic Glossitis, Burning Mouth SyndromeTaiwan
-
University of Sao PauloUnknown
-
Karolinska InstitutetEuropean Society of Pediatric Gastroenterology, Hepatology and NutritionEnrolling by invitationCystic FibrosisPoland, Italy, Norway, Sweden
-
International Centre for Diarrhoeal Disease Research...Global Affairs CanadaRecruitingHealth Behavior | Gestational Weight Gain | Undernutrition | Diet, Food, and NutritionBangladesh
-
Wageningen Centre for Food SciencesCompletedCardiovascular Diseases | HealthyNetherlands